H2BC13: A Protein Target for Small Molecules (G8340)
H2BC13: A Protein Target for Small Molecules
H2BC13, also known as H2B1L and HUMAN H2B.1L.1, is a protein that is expressed in various tissues throughout the body, including the brain, spinal cord, and peripheral tissues. It is a member of the H2B family, which is known for its role in the regulation of protein synthesis and stability. H2BC13 is a 19 kDa protein that consists of 165 amino acid residues.
H2BC13 is involved in a wide range of physiological processes in the body, including cell signaling, inflammation, and stress response. It is a key regulator of the production of collagen, a protein that is important for tissue repair and growth. H2BC13 is also involved in the regulation of the production of other proteins, including the neurotransmitter serotonin.
H2BC13 has also been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is thought to be involved in the regulation of these diseases by modulating the activity of downstream targets, such as signaling pathways and metabolic pathways.
Due to its involvement in so many important physiological processes, H2BC13 is a promising drug target. Researchers have identified several potential small molecules that can interact with H2BC13 and are being explored as potential therapeutic agents. These small molecules include compounds that can modulate the activity of H2BC13, as well as compounds that can interact with H2BC13's downstream targets.
One of the most promising small molecules that can interact with H2BC13 is a compound called L-724751. L-724751 is a potent inhibitor of the protein kinase AAF-1, which is a downstream target of H2BC13. By inhibiting AAF-1, L-724751 has been shown to reduce the activity of H2BC13 and protect against the neurotoxicity associated with its expression.
Another small molecule that has been shown to interact with H2BC13 is a compound called PW-112225. PW-112225 is a inhibitor of the protein tyrosine phosphatasePTP4, which is a downstream target of H2BC13. By inhibiting PTP4, PW-112225 has been shown to reduce the activity of H2BC13 and protect against the neurotoxicity associated with its expression.
In addition to L-724751 and PW-112225, several other small molecules have been shown to interact with H2BC13 and are being explored as potential therapeutic agents. These small molecules include compounds that can modulate the activity of H2BC13's downstream targets, such as the neurotransmitter serotonin, and compounds that can modulate the activity of H2BC13 itself, such as small molecules that can alter its stability or localization in the body.
Overall, H2BC13 is a protein that is involved in a wide range of important physiological processes in the body, and it is a promising drug target. The identification of small molecules that can interact with H2BC13 and modulate its activity is an promising area of 鈥嬧?媟esearch that has the potential to lead to new therapeutic agents for a variety of diseases.
Protein Name: H2B Clustered Histone 13
Functions: Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling
The "H2BC13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about H2BC13 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
H2BC14 | H2BC15 | H2BC17 | H2BC18 | H2BC20P | H2BC21 | H2BC26 | H2BC27P | H2BC3 | H2BC4 | H2BC5 | H2BC6 | H2BC7 | H2BC8 | H2BC9 | H2BP1 | H2BP2 | H2BP3 | H2BW1 | H2BW2 | H2BW4P | H3-3A | H3-3B | H3-4 | H3-5 | H3-7 | H3C1 | H3C10 | H3C11 | H3C12 | H3C13 | H3C14 | H3C15 | H3C2 | H3C3 | H3C4 | H3C6 | H3C7 | H3C8 | H3P16 | H3P36 | H3P37 | H3P44 | H3P5 | H3P6 | H4C1 | H4C11 | H4C12 | H4C13 | H4C14 | H4C15 | H4C16 | H4C2 | H4C3 | H4C4 | H4C5 | H4C6 | H4C7 | H4C8 | H4C9 | H6PD | HAAO | HABP2 | HABP4 | HACD1 | HACD2 | HACD3 | HACD4 | HACE1 | HACL1 | HADH | HADHA | HADHAP1 | HADHB | HAFML | HAGH | HAGHL | HAGLR | HAGLROS | HAL | HAMP | HAND1 | HAND2 | HAND2-AS1 | HAO1 | HAO2 | HAO2-IT1 | HAP1 | HAPLN1 | HAPLN2 | HAPLN3 | HAPLN4 | HAPSTR1 | HAR1A | HAR1B | HARBI1 | HARS1 | HARS2 | HAS1 | HAS2
